antipsychotic agents

Summary

Summary: Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Top Publications

  1. ncbi [Viewpoint of schizophrenic patients: a European survey]
    P Courtet
    , , CHU Montpellier 34295
    Encephale 27:28-38. 2001
  2. ncbi Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
  3. ncbi Tardive dyskinesia rates with atypical antipsychotics in older adults
    Dilip V Jeste
    Division of Geriatric Psychiatry, University of California, San Diego, San Diego, CA, USA
    J Clin Psychiatry 65:21-4. 2004
  4. ncbi Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Lancet 373:31-41. 2009
  5. ncbi Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
  6. ncbi Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
  7. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
  8. ncbi A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Am J Psychiatry 166:152-63. 2009
  9. ncbi Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials
    Claudia Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 127:83-92. 2011
  10. ncbi Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
    Rune A Kroken
    Division of Psychiatry, Haukeland University Hospital, PO Box 23, N 5812, Bergen, Norway
    BMC Psychiatry 9:24. 2009

Detail Information

Publications275 found, 100 shown here

  1. ncbi [Viewpoint of schizophrenic patients: a European survey]
    P Courtet
    , , CHU Montpellier 34295
    Encephale 27:28-38. 2001
    ....
  2. ncbi Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  3. ncbi Tardive dyskinesia rates with atypical antipsychotics in older adults
    Dilip V Jeste
    Division of Geriatric Psychiatry, University of California, San Diego, San Diego, CA, USA
    J Clin Psychiatry 65:21-4. 2004
    ..Using atypical antipsychotics, particularly at lower doses, may aid in preventing symptoms of tardive dyskinesia in older adults...
  4. ncbi Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Lancet 373:31-41. 2009
    ....
  5. ncbi Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  6. ncbi Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 35:581-90. 2010
    ....
  7. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  8. ncbi A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Am J Psychiatry 166:152-63. 2009
    ..The authors conducted a systematic review and meta-analysis of blinded studies comparing second-generation antipsychotics head-to-head...
  9. ncbi Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials
    Claudia Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Res 127:83-92. 2011
    ..Non-adherence is a major problem in the treatment of schizophrenia. Depot antipsychotic drugs are thought to reduce relapse rates by improving adherence, but a systematic review of long-term studies in outpatients is not available...
  10. ncbi Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
    Rune A Kroken
    Division of Psychiatry, Haukeland University Hospital, PO Box 23, N 5812, Bergen, Norway
    BMC Psychiatry 9:24. 2009
    ..The objective of this study was to evaluate the practice of treatment of schizophrenic patients with antipsychotics at discharge from acute inpatient settings at a national level...
  11. ncbi Management of behavioral problems in Alzheimer's disease
    Serge Gauthier
    Alzheimer s Disease and Related Disorders Unit, McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Canada
    Int Psychogeriatr 22:346-72. 2010
    ..Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class...
  12. ncbi Bipolar depression: overview and commentary
    Ross J Baldessarini
    Harvard Medical School, McLean Hospital, Belmont, MA, USA
    Harv Rev Psychiatry 18:143-57. 2010
    ..Interest in recognizing bipolar depression and seeking more effective, specific, and safer treatments for it are growing...
  13. ncbi Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Terry E Goldberg
    Zucker Hillside Hospital, 7559 263rd Street, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 64:1115-22. 2007
    ..However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects...
  14. ncbi Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial
    Mette Bertelsen
    Bispebjerg Hospital, Department of Psychiatry, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark
    Arch Gen Psychiatry 65:762-71. 2008
    ..Intensive early treatment for first-episode psychosis has been shown to be effective. It is unknown if the positive effects are sustained for 5 years...
  15. ncbi Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Res 102:230-40. 2008
    ..To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients with schizophrenia...
  16. ncbi Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review
    Viktoria Simon
    Department of Psychiatry and Psychotherapy, Semmelweis University Budapest, Hungary
    J Clin Psychiatry 70:1041-50. 2009
    ..Numerous publications have provided evidence for clinically important metabolic adverse effects of antipsychotics, but there is no systematic evaluation as to whether weight gain and other metabolic changes are dose dependent...
  17. ncbi Tardive dyskinesia and new antipsychotics
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Curr Opin Psychiatry 21:151-6. 2008
    ..To provide an update on tardive dyskinesia rates in patients treated with first-generation or second-generation antipsychotics in studies published since the last systematic review in 2004...
  18. ncbi Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Schizophr Bull 34:1163-71. 2008
    ..This study assessed the predictive accuracy of early nonresponse to treatment and its clinical, functional, and economic ramifications in the naturalistic treatment of predominately chronic outpatients treated for schizophrenia...
  19. ncbi Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories
    Stephen Z Levine
    Bar Ilan University, Ramat Gan, Israel
    Biol Psychiatry 68:86-92. 2010
    ..To extend the early treatment response literature, this article aims to quantify the extent of heterogeneity and describe the characteristics of treatment response trajectories in schizophrenia...
  20. ncbi Trajectories and antecedents of treatment response over time in early-episode psychosis
    Stephen Z Levine
    Bar Ilan University, Ramat Gan, Israel
    Schizophr Bull 36:624-32. 2010
    ..The current study aims to quantify the extent of heterogeneity in trajectories of treated symptom severity in early-episode psychosis and their antecedents...
  21. ncbi Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
    J Affect Disord 126:358-65. 2010
    ..We report the results of long-term treatment with asenapine in patients with bipolar I disorder...
  22. ncbi Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension
    Andreas Tzimos
    Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece
    Am J Geriatr Psychiatry 16:31-43. 2008
    ..The study was not powered to show statistical differences...
  23. ncbi Risperidone and paliperidone inhibit p-glycoprotein activity in vitro
    Hao Jie Zhu
    Laboratory of Drug Disposition and Pharmacogenetics, Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC, USA
    Neuropsychopharmacology 32:757-64. 2007
    ..In particular, RSP may interact with its own active metabolite PALI by promoting its brain concentration through inhibiting P-gp-mediated efflux of PALI across endothelial cells of the BBB...
  24. ncbi Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
    Michael F Green
    Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine at UCLA, USA
    Schizophr Res 72:41-51. 2004
    ..These steps are apt to have important implications for clinical trials of cognition-enhancing agents in schizophrenia...
  25. ncbi Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..CONCLUSIONS: Long-acting injectable risperidone was efficacious and well tolerated and provides both clinicians and patients with a new mode of treatment that can improve the outcome of long-term therapy...
  26. ncbi Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt Medical Center, Nashville, TN, USA
    J Clin Psychiatry 69:817-29. 2008
    ..To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily...
  27. ncbi Methodological issues in current antipsychotic drug trials
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Bull 34:275-85. 2008
    ..The authors present practical examples to highlight the current problems and propose a concrete series of suggestions on how to further optimize antipsychotic drug trials in the future...
  28. ncbi Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial
    Steven G Potkin
    Department of Psychiatry and Human Behavior, University of California, Irvine, Brain Imaging Center, CA 92697 3960, USA
    J Clin Psychiatry 68:1492-500. 2007
    ..This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria)...
  29. ncbi Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients
    Jimmi Nielsen
    Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aarhus University Hospital, Mølleparkvej 10, Aalborg, Denmark
    Neuropsychopharmacology 35:1997-2004. 2010
    ..Patients discontinuing olanzapine or mid-potency FGA had no increased risk of diabetes compared with patient not treated with the drugs at anytime...
  30. ncbi Review of lithium effects on brain and blood
    Wise Young
    W M Keck Center for Collaborative Neuroscience, Rutgers, State University of New Jersey, Piscataway, NJ 08854, USA
    Cell Transplant 18:951-75. 2009
    ..Clinical trials assessing the effects of lithium are under way. A recent clinical trial suggests that lithium stops the progression of ALS...
  31. ncbi Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
    ..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
  32. ncbi Long-acting risperidone and oral antipsychotics in unstable schizophrenia
    Robert A Rosenheck
    Veterans Affairs VA New England Mental Illness, Research Education and Clinical Center, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    N Engl J Med 364:842-51. 2011
    ....
  33. ncbi Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Eduardo Dunayevich
    Outcomes Research, Eli Lilly and Co, Indianapolis, IN, USA
    J Clin Psychiatry 68:1163-71. 2007
    ..This study examines whether longer time to all-cause medication discontinuation is also linked to better functional outcomes...
  34. ncbi Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected
    Ofer Agid
    Schizophrenia Program and the PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Gen Psychiatry 60:1228-35. 2003
    ..Furthermore, greater improvement occurs in the first 2 treatment weeks than in the subsequent 2 treatment weeks. Proposed mechanisms of action of antipsychotic drugs need to account for this early-onset antipsychotic effect...
  35. ncbi Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic
    W Wolfgang Fleischhacker
    Department of Biological Psychiatry, Innsbruck University Clinics, Anichstrasse 35, 6020 Innsbruck, Austria
    J Clin Psychiatry 64:1250-7. 2003
    ..The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia...
  36. ncbi Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects
    Yvette Roke
    Symfora Group Psychiatric Center, Amersfoort, The Netherlands
    J Child Adolesc Psychopharmacol 19:403-14. 2009
    ..This review reports the incidence of hyperprolactinemia, its relationship with genotype, and prolactin-related side effects in children and adolescents treated with antipsychotics...
  37. ncbi Acute and long-term treatment of mania
    Eduard Vieta
    Bipolar Disorders Program, University of Barcelona, Hospital Clinic, IDIBAPS, CIBER SAM, Barcelona, Catalonia, Spain
    Dialogues Clin Neurosci 10:165-79. 2008
    ..Psychoeducation of patients and caregivers is a powerful tool that should be used in combination with medication for optimal long-term outcome. Functional recovery should be the ultimate goal...
  38. ncbi Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia
    Sahebarao P Mahadik
    Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, 30904, USA
    Int Rev Psychiatry 18:119-31. 2006
    ....
  39. ncbi Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program
    Matthew Menza
    Department of Psychiatry, Robert Wood Johnson Medical School, D207A, 671 Hoes Lane, Piscataway, NJ 08854, USA
    J Clin Psychiatry 65:471-7. 2004
    ....
  40. ncbi Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials
    Mario Alvarez-Jimenez
    ORYGEN Research Centre, University of Melbourne, Victoria, Australia
    Br J Psychiatry 193:101-7. 2008
    ..Antipsychotic-induced weight gain is a major concern in the treatment of psychosis. The efficacy of non-pharmacological interventions as well as the optimal intervention approach for this side-effect remain unclear...
  41. ncbi Dorsolateral prefrontal cortex activity predicts responsiveness to cognitive-behavioral therapy in schizophrenia
    Veena Kumari
    Department of Psychology, Institute of Psychiatry, King s College London, United Kingdom
    Biol Psychiatry 66:594-602. 2009
    ....
  42. ncbi Compelling or irrelevant? Using number needed to treat can help decide
    L Citrome
    Department of Psychiatry, New York University School of Medicine, The Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Acta Psychiatr Scand 117:412-9. 2008
    ....
  43. ncbi Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, Titusville, NJ, USA
    Am J Psychiatry 166:691-701. 2009
    ..The authors compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization...
  44. ncbi Ziprasidone monotherapy in bipolar II depression: an open trial
    Michael R Liebowitz
    The Medical Research Network, LLC, New York, NY 10024, USA
    J Affect Disord 118:205-8. 2009
    ....
  45. ncbi Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts
    Cathy Budman
    North Shore University Hospital Long Island Jewish Hospital System, Manhasset, New York
    J Child Adolesc Psychopharmacol 18:509-15. 2008
    ..We conducted a retrospective, observational study of aripiprazole for the treatment of tics and/or co-morbid explosive outbursts in 37 children and adolescents with Tourette disorder (TD)...
  46. ncbi Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Biol Psychiatry 57:1543-9. 2005
    ....
  47. ncbi HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study
    Hans Mulder
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    J Clin Psychopharmacol 29:16-20. 2009
    ..The increased risk for the metabolic syndrome is particularly strong in carriers of the rs1414334 C allele using clozapine or risperidone...
  48. ncbi Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study
    Gholson J Lyon
    New York University Child Study Center, New York, New York 10016, USA
    J Child Adolesc Psychopharmacol 19:623-33. 2009
    ..The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD)...
  49. ncbi Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia
    Faranak Farzan
    Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, M5T 1R8, Canada
    Brain 133:1505-14. 2010
    ....
  50. ncbi Adverse effects of atypical antipsychotics : differential risk and clinical implications
    Peter M Haddad
    Cromwell House Community Mental Health Centre, Manchester, England
    CNS Drugs 21:911-36. 2007
    ..Selection of an antipsychotic should be on an individual patient basis. Patients should be involved in prescribing decisions and this should involve discussion about adverse effects...
  51. ncbi Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
    ..While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity...
  52. ncbi Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia
    Donald L Patrick
    University of Washington, Seattle, WA 98195 9455, USA
    Curr Med Res Opin 25:325-38. 2009
    ..To describe the measurement properties of the Personal and Social Performance scale (PSP), a clinician-reported measure of severity of personal and social dysfunction, in subjects with acute symptoms of schizophrenia...
  53. ncbi Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory
    M S Barr
    Schizophrenia Program, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Schizophr Res 121:146-52. 2010
    ..These findings may provide important insights into the pathophysiology underlying WM deficits, its relationship to negative symptoms and may represent a potential neurobiological marker for cognitive enhancing strategies in SCZ...
  54. ncbi Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
    Lizheng Shi
    School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, New Orleans, LA 70112, USA
    BMC Psychiatry 9:80. 2009
    ..To examine the baseline metabolic monitoring (MetMon) for second generation antipsychotics (SGA) among patients with schizophrenia in the Veterans Integrated Service Network (VISN) 16 of the Veterans Health Administration (VHA)...
  55. ncbi The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression
    Heinz Grunze
    Newcastle University, RVI, Division of Psychiatry, Institute of Neuroscience, Newcastle upon Tyne, UK
    World J Biol Psychiatry 11:81-109. 2010
    ..Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults...
  56. ncbi A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder
    Eduard Vieta
    Institute of Neuroscience, University of Barcelona Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain
    Bipolar Disord 12:230-43. 2010
    ..To evaluate the antimanic efficacy and safety of paliperidone extended-release (ER) tablets in patients with bipolar I disorder...
  57. ncbi Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial
    Wolfgang Gaebel
    Department of Psychiatry and Psychotherapy, Heinrich Heine University, Dusseldorf, Germany
    Neuropsychopharmacology 35:2367-77. 2010
    ..Both antipsychotics were generally well tolerated...
  58. ncbi National trends in psychotropic medication polypharmacy in office-based psychiatry
    Ramin Mojtabai
    Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 797, Baltimore, MD 21205, USA
    Arch Gen Psychiatry 67:26-36. 2010
    ..Psychotropic medication polypharmacy is common in psychiatric outpatient settings and, in some patient groups, may have increased in recent years...
  59. ncbi Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study
    Lone Baandrup
    Centre for Neuropsychiatric Schizophrenia Research, Psychiatric Centre Glostrup, Copenhagen University Hospital, Glostrup, Nordre Ringvej 29 67, DK 2600 Glostrup, Denmark
    J Clin Psychiatry 71:103-8. 2010
    ..The objective was to investigate if antipsychotic polypharmacy is associated with the excess mortality from natural causes among patients with schizophrenia...
  60. ncbi Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
    Virginia L Stauffer
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychiatry Res 187:42-8. 2011
    ..As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis...
  61. ncbi Quetiapine treatment of children with Tourette's syndrome: report of two cases
    H C Parraga
    Fourth Street Clinic, Springfield, Illinois 62703, USA
    J Child Adolesc Psychopharmacol 11:187-91. 2001
    ..Controlled studies are needed to determine the efficacy of quetiapine in the treatment of Tourette's syndrome...
  62. ncbi The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland at Baltimore, School of Medicine, USA
    Schizophr Res 90:186-97. 2007
    ..To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia...
  63. ncbi Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death
    A H Glassman
    Department of Clinical Psychopharmacology, New York State Psychiatric Institute, New York 10032, USA
    Am J Psychiatry 158:1774-82. 2001
    ..The authors review the mechanisms and establish the risk of torsade de pointes and sudden death with antipsychotic drugs...
  64. ncbi Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme
    Marie Josée Poulin
    Centre Hospitalier Affilie Universitaire De Quebec, Hôpital de l Enfant Jésus and Centre Hospitalier Robert Giffard, Quebec City, Quebec, Canada
    Aust N Z J Psychiatry 41:980-9. 2007
    ....
  65. ncbi Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome
    Michael H Bloch
    Yale Child Study Center, and General Clinical Research Center, Yale University School of Medicine, New Haven, CT 06520-7900, USA
    Arch Pediatr Adolesc Med 160:65-9. 2006
    ..CONCLUSION: Obsessive-compulsive disorder symptoms in children with TS became more severe at a later age and were more likely to persist than tic symptoms...
  66. ncbi Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics
    Georg Juckel
    Department of Psychiatry, , , Schumannstr. 20/21, Berlin 10117, Germany
    Psychopharmacology (Berl) 187:222-8. 2006
    ..Significant blunting of ventral striatal activation was not observed in patients treated with atypical neuroleptics, which may reflect the improved efficacy of these drugs in treating negative symptoms...
  67. ncbi Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial
    Jun Soo Kwon
    Department of Psychiatry, Seoul National University College of Medicine, Chongno Gu, Seoul, Korea
    J Clin Psychiatry 67:547-53. 2006
    ..The effects of the weight management program were also assessed with regard to safety and quality of life...
  68. ncbi Quetiapine treatment of children and adolescents with Tourette's disorder
    Nahit Motavali Mukaddes
    Istanbul University, Child and Adolescent Psychiatry Department, Medical Faculty of Istanbul, Istanbul, Turkey
    J Child Adolesc Psychopharmacol 13:295-9. 2003
    ..The purpose of this study was to investigate the short-term safety and effectiveness of quetiapine in the treatment of children and adolescents with Tourette's disorder...
  69. ncbi Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain
    Gavin P Reynolds
    Department of Biomedical Science, University of Sheffield, UK
    Am J Psychiatry 160:677-9. 2003
    ..The authors determined whether this association held true for weight gain after clozapine treatment...
  70. ncbi An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders
    Hanik K Yoo
    Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Clin Psychiatry 68:1088-93. 2007
    ....
  71. ncbi Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study
    Mark Taylor
    Springpark Centre, Glasgow, United Kingdom
    J Clin Psychiatry 69:240-5. 2008
    ..There are few independent studies comparing atypical or second-generation antipsychotics (SGAs)...
  72. ncbi A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence
    Keming Gao
    Department of Psychiatry, Bipolar Disorder Research Center at Mood Disorders Program, University Hospitals Case Medical Center Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA
    J Clin Psychiatry 69:302-9. 2008
    ..This study compared the sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia...
  73. ncbi A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
    Donald C Goff
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neuropsychopharmacology 33:465-72. 2008
    ..CX516 was not effective for cognition or for symptoms of schizophrenia when added to clozapine, olanzapine, or risperidone...
  74. ncbi Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables
    Benedicto Crespo-Facorro
    Hospital Universitario Marques de Valdecilla, Department of Psychiatry, School of Medicine, planta 2a, Edificio 2 de Noviembre, Avda Valdecilla s n, 39008, Santander, Spain
    J Psychiatr Res 41:659-66. 2007
    ..Helping clinicians to identify non-responders is meant as a first step to optimise therapeutic effort to benefit individuals in this vulnerable group...
  75. ncbi Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats
    Nurith Amitai
    Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive, Mail Code 0603, La Jolla, CA 92093 0603, USA
    Psychopharmacology (Berl) 193:521-37. 2007
    ..The development and validation of animal models of cognitive deficits characterizing schizophrenia are crucial for clarifying the underlying neuropathology and discovery of improved treatments for such deficits...
  76. ncbi Treatment of psychosis: 30 years of progress
    I R de Oliveira
    Department of Neuropsychiatry, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil
    J Clin Pharm Ther 31:523-34. 2006
    ..We can envisage different therapeutic strategies in the future, each uniquely targeting a different dimension of schizophrenia, be it positive, negative, cognitive or affective symptoms...
  77. ncbi Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study
    Xiaohong Wang
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Drive, Suite 4000, Atlanta, GA 30322, United States
    J Psychiatr Res 40:669-76. 2006
    ..Atypical antipsychotic agents were then administered alone (monotherapy) for 12 weeks...
  78. ncbi Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder
    Menahem I Krakowski
    Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Arch Gen Psychiatry 63:622-9. 2006
    ..Violent behavior of patients with schizophrenia prolongs hospital stay and interferes with their integration into the community. Finding appropriate treatment of violent behaviors is of primary importance...
  79. ncbi Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:1050-60. 2007
    ....
  80. ncbi Early use of clozapine for poorly responding first-episode psychosis
    Ofer Agid
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 27:369-73. 2007
    ....
  81. ncbi Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
    ..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis...
  82. ncbi [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]
    Szendi István
    SZTE Pszichiátriai Klinika, Szeged, Hungary
    Neuropsychopharmacol Hung 9:115-24. 2007
    ..Extrapyramidal symptoms of patients treated with olanzapine improved significantly better compared with those patients who received other antipsychotics and risperidone respectively...
  83. ncbi Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders
    L N Gorobets
    Department of Psychiatric Endocrinology, Moscow Institute of Psychiatry, Federal Agency of Public Health and Social Development
    Bull Exp Biol Med 140:714-5. 2005
    ..We evaluated the specific effects of the test drugs on prolactin concentration in men and women...
  84. ncbi A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial
    Emilio Sacchetti
    Department of Psychiatry, Brescia University School of Medicine, Brescia, Italy
    Schizophr Res 98:55-65. 2008
    ..In conclusion, quetiapine, risperidone, and olanzapine have similar efficacy in schizophrenia, but there are drug-specific differences for some AEs and in the use of concomitant medication that differentiate these agents...
  85. ncbi Analysis of treatment effectiveness in longitudinal observational data
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Biopharm Stat 17:809-26. 2007
    ..Marginal structural models are a promising approach to estimation of causal treatment effects in such data...
  86. ncbi Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation
    Vincenzo Villari
    Emergency Department, Psychiatric Emergency Service, S Giovanni Hospital, Corso Bramante 88, 10126 Turin, Italy
    Prog Neuropsychopharmacol Biol Psychiatry 32:405-13. 2008
    ..GENERAL METHODS: We recruited 101 patients with acute psychosis who were admitted at the Mental Health Department 1 South of Turin, Psychiatric Emergency Service of San Giovanni Battista Hospital, from June 2004 to June 2005...
  87. ncbi Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
    Suzanne M Archie
    Department of Psychiatry and Behavioural Neurosciences, McMaster University, 25 Charlton Ave, East, Suite 703, Hamilton, Ontario, Canada L8N 1Y2
    Psychiatr Serv 58:233-9. 2007
    ..This study compared characteristics of patients in Canada who had a psychotic disorder and were ready to make lifestyle changes with characteristics of patients who were not considering lifestyle changes...
  88. ncbi Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  89. ncbi Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial
    Jonathan K Wynn
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
    Schizophr Res 95:134-42. 2007
    ..The results are discussed in terms of animal models, neural substrates, and treatment implications...
  90. ncbi Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:632-7. 2006
    ....
  91. ncbi The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
    Antonio Ciudad
    Clinical Research, Department of Research and Development, Lilly, S A Avda de la Industria, 30, 28108 Alcobendas, Madrid, Spain
    Eur Psychiatry 23:1-7. 2008
    ..This article presents the long-term results in terms of antipsychotic medication maintenance and factors influencing it in a representative sample of patients with schizophrenia recruited in the SOHO study within Spain...
  92. ncbi Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  93. ncbi A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis
    Benedicto Crespo-Facorro
    University Hospital Marques de Valdecilla, Department of Psychiatry, Santander, Spain
    J Clin Psychiatry 67:1511-21. 2006
    ....
  94. ncbi Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study
    S Craig Risch
    Langley Porter Psychiatric Institute, University of California San Francisco 94143 0984, USA
    Schizophr Res 93:131-5. 2007
    ..018, n=13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia...
  95. ncbi Did CATIE influence antipsychotic use?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:476. 2008
  96. ncbi A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia
    Herbert Y Meltzer
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    J Clin Psychiatry 69:274-85. 2008
    ..There are conflicting data concerning the potential utility of olanzapine in treatment-resistant schizophrenia at doses beyond the 10- to 20-mg/day range that has proven to be effective for most nonrefractory patients with schizophrenia...
  97. ncbi Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol
    Mark J Sergi
    Department of Psychology, California State University, 18111 Nordhoff St, Northridge, CA 91330 8255, USA
    Am J Psychiatry 164:1585-92. 2007
    ..This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition...
  98. ncbi Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  99. ncbi Atypical antipsychotics in the treatment of children and adolescents: clinical applications
    Robert L Findling
    Department of Psychiatry, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106 5080, USA
    J Clin Psychiatry 65:30-44. 2004
    ..Evidence on the use of atypical antipsychotics in children and adolescents is summarized in this review...
  100. ncbi COMT158 polymorphism and hostility
    Jan Volavka
    Nathan Kline Institute, Orangeburg, New York 10982, USA
    Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004
    ..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
  101. ncbi Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...

Research Grants80

  1. Sedative Hypnotic Use by the Mentally Ill: A Medicaid Prescription Policy Study
    Judy Zerzan; Fiscal Year: 2009
    ....
  2. Medicare Drug Benefits and High Cost Medications: Antipsychotics Under Part D
    Vicki Fung; Fiscal Year: 2011
    ....
  3. Endogenous Kynurenic Acid Modulates Prefrontal ACh Levels and Cognitive Behavior
    Robert Schwarcz; Fiscal Year: 2010
    ....
  4. MOTOR EFFECTS OF ATYPICAL ANTIPSYCHOTICS
    John Salamone; Fiscal Year: 2003
    ..Taken together, the results of these experiments will help to identify the pharmacological characteristics and brain circuits that underlie the motor effects of clozapine. ..
  5. Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
    Karen Teff; Fiscal Year: 2009
    ..Findings from these studies will have important clinical relevance to the treatment of schizophrenia. ..
  6. Atypical Antipsychotics: Effects on Hepatic Glucose and Lipid Metabolism in Human
    Karen L Teff; Fiscal Year: 2010
    ..Findings from these studies will have important clinical relevance to the treatment of schizophrenia. ..
  7. BIOPHYSICAL STUDY OF ANTIPSYCHOTICS BEHAVIORAL EFFECTS
    Stephen Fowler; Fiscal Year: 2003
    ....
  8. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2007
    ..This information will help to provide a more rational basis for making treatment decisions concerning children and adolescents who may benefit from treatment with an antipsychotic. ..
  9. MECHANISMS OF CARDIOTOXICITY OF ANTIPSYCHOTIC DRUGS
    David Flockhart; Fiscal Year: 2001
    ..3) To determine if antipsychotic agents that are found to be potentially cardiotoxic in vitro have clinical electrocardiac effects at the doses ..
  10. Deconstructing Clozapine: Toward Medication for Alcoholism in Schizophrenia
    Alan I Green; Fiscal Year: 2010
    ....
  11. Antipsychotic Drugs and Maternal Behavior: A Preclinical Investigation
    Ming Li; Fiscal Year: 2007
    ....
  12. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
    Elaine Peskind; Fiscal Year: 2009
    ..Prazosin blocks the excessive brain adrenaline arousal that contributes to agitation in AD and both therapeutic and tolerability results of our prazosin feasibility study are very promising. ..
  13. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
    Elaine R Peskind; Fiscal Year: 2010
    ..Prazosin blocks the excessive brain adrenaline arousal that contributes to agitation in AD and both therapeutic and tolerability results of our prazosin feasibility study are very promising. ..
  14. Dopamine action in pancreatic islet function
    David W Piston; Fiscal Year: 2010
    ....
  15. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. ..
  16. Comparative Safety of Atypical Antipsychotics in High-Risk US Children with ADHD
    David M Rubin; Fiscal Year: 2010
    ....
  17. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. ..
  18. Contribution of cell cycle processes to myelin deficits in schizophrenia
    Vahram Haroutunian; Fiscal Year: 2009
    ..Published results from us and others suggest that antipsychotic agents can influence OMR gene expression, but the direction of effect is unclear and how these pharmacological ..
  19. NEUROTENSIN--AN ENDOGENOUS NEUROLEPTIC LIKE PEPTIDE
    Charles Nemeroff; Fiscal Year: 1999
    ..These studies will provide novel information concerning the role of NT systems in the mechanism of action of antipsychotic drugs, and in the pathophysiology of schizophrenia. ..
  20. Negative symptoms of schizophrenia: animal models
    Athina Markou; Fiscal Year: 2009
    ....
  21. Negative symptoms of schizophrenia: animal models
    Athina Markou; Fiscal Year: 2010
    ....
  22. Treatment of Psychotic Disorders in Youth
    Linmarie Sikich; Fiscal Year: 2006
    ....
  23. Serotonin Glutamate Interactions in Prefrontal Cortex
    Gerard Marek; Fiscal Year: 2001
    ..As such, this multi-disciplinarian study may provide new strategies to develop novel antidepressant treatments that would be more efficacious than simply blocking 5-HT2A receptors. ..
  24. Antipsychotic Influence on Altered MTL Neuronal Activity in Schizophrenia
    Carol Tamminga; Fiscal Year: 2009
    ..We propose to test the elements of this model with in vivo brain imaging using measures of basal activity and relational memory probes, correlating alterations in neural activity with characteristics of the illness. ..
  25. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan I Green; Fiscal Year: 2010
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  26. Molecular basis of atypical antipsychotic drugs-induced weight gain
    Sangwon F Kim; Fiscal Year: 2010
    ..Hence, it is upmost importance to identify the molecular mechanism of how AAPDs lead to an excessive weight gain. ..
  27. Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?
    Alan Green; Fiscal Year: 2009
    ..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
  28. Antipsychotics and Mortality in Older Patients
    HELEN KALES; Fiscal Year: 2007
    ..our prior work to examine further critical questions including: 1) comparing mortality risks for individual antipsychotic agents in older patients both with and without dementia diagnoses in the 12 months following a new antipsychotic ..
  29. Antipsychotics and Mortality in Older Patients
    HELEN KALES; Fiscal Year: 2009
    ..our prior work to examine further critical questions including: 1) comparing mortality risks for individual antipsychotic agents in older patients both with and without dementia diagnoses in the 12 months following a new antipsychotic ..